CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Inhaled Placebo +1 moredrug
Likely dose
Inhaled Loxapine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00789360
NCT00789360Phase 1Completed
CompareCT.gov

Pulmonary Safety of Repeat Doses of Staccato® Loxapine for Inhalation in Healthy Volunteers

Alexza Pharmaceuticals, Inc.·interventional·Posted Nov 11, 2008·Updated Mar 11, 2019

In Brief

A Phase 1 clinical trial evaluating Inhaled Placebo and Inhaled Loxapine for Healthy. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato Loxapine within a day.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2008
Enrollment StartNov 1, 2008
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.6 years ago

Interventions

Inhaled Placebodrug

Inhaled Staccato Placebo, 2 inhalations, 8 hours apart

Inhaled Loxapinedrug

Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart